한건희 (고려대학교, 한국과학기술연구원(KIST)) | 한빛사논문 > 한빛사

한빛사논문

조회289

고려대학교, 한국과학기술연구원(KIST)

CV File 422 kb

Adv. Drug Deliv. Rev., Available online 25 June 2023 | https://doi.org/10.1016/j.addr.2023.114973 Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery

Geonhee Han ^a,b, Dahye Noh ^b,c,e, Hokyung Lee ^b,d, Sangmin Lee ^d, Sehoon Kim ^a,d, Hong Yeol Yoon ^b,c, Soo Hyeon Lee ^f

^aKU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea
^bMedicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea
^cDivision of Bio-Medical Science &Technology, KIST School, University of Science and Technology, Hwarang-ro14-gil 5, Seongbuk-gu, Seoul, Republic of Korea 02792
^dDepartment of Fundamental Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 02447, Republic of Korea
^eChemical and Biological Integrative Research Center, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea
^fMolecular Surgery Laboratory, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, CA 94304, USA

Corresponding authors : Hong Yeol Yoon, Soo Hyeon Lee

Abstract

RNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing proteins and protein fragments for cancer immunotherapy is now being explored. Despite the promise, the use of mRNA in cancer immunotherapy is limited by challenges, such as low stability against extracellular RNases, poor delivery efficiency to the target organs and cells, short circulatory half-life, variable expression levels and duration. This review highlights recent advances in chemical modification and advanced delivery systems that are helping to address these challenges and unlock the biological and pharmacological potential of mRNA therapeutics in cancer immunotherapy. The review concludes by discussing future perspectives for mRNA-based cancer immunotherapy, which holds great promise as a next-generation therapeutic modality.

논문정보

형식Review Paper
게재일2023년 06월 (BRIC 등록일 2023-08-18)
연구진국내(교신)+국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기